Video Reports

Omidubicel met the primary end point of time to neutrophil engraftment in patients with high-risk hematologic malignancies undergoing a bone marrow transplant, according to topline findings from a phase 3 trial announced by Gamida Cell Ltd., the developer of the investigational advanced cell therapy.

Anna C. Pavlick, DO, professor in the Department of Medicine and Ronald O. Perelman Department of Dermatology, as well as the director of High Reliability Organization Initiatives and the co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, discusses updated results from the COLUMBUS trial in metastatic melanoma.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses emerging immunotherapy combinations in melanoma.

Jason J. Luke, MD, FACP, associate professor of medicine, Division of Hematology/Oncology, and director of the Cancer Immunotherapeutics Center within the Immunology and Immunotherapy Program, University of Pittsburgh Medical Center Hillman Cancer Center, discusses predictive biomarkers in metastatic melanoma.